(BMY) Bristol-Myers Squibb Company Company Overview

What does Bristol Myers Squibb do?

Bristol Myers Squibb Company is a global biopharmaceutical company listed on the New York Stock Exchange under the ticker BMY. Its core activity is not retail pharmacy, hospital operation, or generic manufacturing. It discovers, develops, licenses, manufactures, markets, distributes, and sells prescription medicines for serious diseases. In its 2025 Form 10-K, the company says it operates as a single segment and concentrates its science and commercial effort in oncology, hematology, immunology, cardiovascular disease, neuroscience, and selected adjacent areas.

Why does the company matter in healthcare?

BMS matters because it sits at the high-risk, high-reward end of healthcare: patented medicines, long clinical development cycles, regulated manufacturing, specialist sales channels, payer reimbursement, and patent cliffs. Its products include large established franchises such as Eliquis and Opdivo, newer growth brands such as Reblozyl, Breyanzi, Camzyos, Opdualag, Opdivo Qvantig, and Cobenfy, and a development pipeline that must replace revenue as older drugs lose exclusivity. The company's own public site frames its work as “World-class science. Life-changing impact,” while reporting a pipeline of 50 compounds across more than 40 disease areas as of April 30, 2026 on its official company site.

How does Bristol Myers Squibb make money?

The business model is product-led. BMS sells branded medicines mainly to wholesalers, distributors, specialty pharmacies, and, to a lesser extent, retailers, hospitals, clinics, government agencies, and patients. It also earns alliance and royalty revenue, but the main revenue engine is net product sales after charge-backs, rebates, discounts, returns, and other gross-to-net adjustments.

What is the revenue formula?

The strategic tension is visible in gross-to-net adjustments. FY2025 gross product sales were $88.085B, but total gross-to-net adjustments were $41.329B, leaving $46.756B of net product sales. BMS attributes these deductions to charge-backs, cash discounts, Medicare and Medicaid rebates, other rebates, returns, and related adjustments. That makes payer mix and policy changes central to valuation, not a footnote.

Which products and portfolios matter most?

BMS does not report separate operating segments by franchise; it reports one company-wide segment. For analysis, the more useful internal lens is product portfolio. The Growth Portfolio supplied $26.409B of FY2025 revenue, while the Legacy Portfolio supplied $21.785B. That mix matters because BMS is trying to move investor attention from older patent-cliff exposure toward products that can sustain revenue through the late 2020s.

Which products generate the most revenue?

What does the latest quarter show?

The newest official reporting package available before this article is BMS's first quarter 2026 reporting for the three months ended March 31, 2026. In the Q1 2026 Form 10-Q, total revenue increased to $11.489B from $11.201B in Q1 2025, while net earnings attributable to BMS increased to $2.677B from $2.456B. The quarter was not a simple growth story: Growth Portfolio strength and Eliquis demand offset continuing declines in Revlimid, Sprycel, Abraxane, and parts of the legacy base.

What changed from Q1 2025?

BMS's Q1 2026 earnings release also shows the importance of product-level mix: Eliquis revenue was $4.137B, Opdivo was $2.146B, Orencia was $818M, Yervoy was $651M, Reblozyl was $555M, and Breyanzi was $411M in the quarter.

What turning points shaped Bristol Myers Squibb's strategy?

The company's current shape is the result of several strategic turns rather than one product launch. The official company history timeline shows a long movement from broad pharmaceutical products toward specialized, science-led biopharma. For analysis, the most relevant events are those that still affect today's product mix, R&D platforms, and patent-cliff exposure.

1. 1887
   The predecessor New York business was founded; today's 10-K traces the company lineage to that origin, but the modern investment story is much more specialized than the early consumer and pharmaceutical mix.
2. 1989
   Bristol-Myers and Squibb combined, creating the corporate platform that later narrowed around innovative medicines.
3. 2009
   The Medarex acquisition expanded oncology and immunology capabilities, helping build the immuno-oncology base behind Opdivo.
4. 2012
   Eliquis was approved, creating the cardiovascular franchise that remains the company's largest product line by FY2025 revenue.
5. 2014
   Opdivo was approved, cementing BMS as a major immuno-oncology company and making oncology rivalry central to its competitive analysis.
6. 2019
   The Celgene acquisition added hematology scale, Revlimid cash flows, and future patent-cliff pressure, while also adding assets such as Reblozyl and cell therapy capabilities.
7. 2020-2024
   MyoKardia, Turning Point, Mirati, RayzeBio, and Karuna expanded cardiovascular, precision oncology, radiopharmaceutical, and neuroscience exposure.

What did those moves change?

The historical pattern is clear: BMS uses a blend of internal science, alliances, and large acquisitions to renew the portfolio. That can create powerful marketed products, but it also creates integration costs, acquired intangible amortization, debt, and R&D execution risk. The 2019 Celgene transaction is the clearest case study. It gave BMS scale in hematology and cell therapy, but it also tied the company to the decline curve of Revlimid and Pomalyst/Imnovid as generic competition expands.

What gives Bristol Myers Squibb a competitive advantage?

BMS's moat is not a consumer brand moat in the classic sense. It is a regulated-science moat built from patents, clinical evidence, specialist physician adoption, manufacturing know-how, reimbursement access, alliances, and the ability to fund repeated R&D cycles. The company competes with global research-based drug companies, focused biotech firms, and generic manufacturers; its own filings emphasize that innovative medicines can lose substantial revenue quickly when market exclusivity expires.

Where is the moat strongest?

The strongest advantage appears where BMS has a differentiated medicine, a large physician and patient evidence base, meaningful patent or regulatory protection, and enough commercial scale to defend access. Opdivo and Yervoy show the value of oncology combinations and indication expansion. Eliquis shows the value of a large cardiovascular standard-of-care franchise. Breyanzi, Reblozyl, Camzyos, and Cobenfy show the company's attempt to build newer, more durable growth pillars.

How financially strong is Bristol Myers Squibb?

BMS remains a large, profitable, cash-generative pharmaceutical company, but its balance sheet is shaped by acquisition-led portfolio renewal. FY2025 total revenue was essentially flat at $48.194B, net earnings attributable to BMS were $7.054B, operating cash flow was $14.156B, and capital expenditures were $1.311B. The company paid $5.045B of dividends in FY2025, while also carrying substantial debt from strategic transactions.

What does the balance sheet say?

How does capital allocation affect the story?

The Q1 2026 results presentation states that BMS is pursuing business development, maintaining balance-sheet strength, and returning cash to shareholders, with about $5B of share repurchase authorization remaining as of March 31, 2026. But the company also paid $1.283B of dividends, repaid $500M of long-term debt, and generated $1.104B of operating cash flow in Q1 2026. That mix explains why investors watch free cash flow conversion closely.

Who owns Bristol Myers Squibb stock?

BMS has a dispersed public-company ownership profile rather than a founder-controlled share structure. The latest 2026 proxy statement reports 2,041,735,455 common shares and 2,246 convertible preferred shares outstanding and entitled to vote as of March 12, 2026. No director or executive officer, individually or as a group, beneficially owned more than 1% of the outstanding common or preferred stock.

How do governance and leadership influence analysis?

Christopher Boerner is Board Chair and Chief Executive Officer; his official profile notes that he became chief executive after serving as chief operating officer and chief executive officer designate in 2023, and previously led commercial and medical organizations. The leadership profile is relevant because BMS's near-term problem is commercial execution and portfolio transition, not merely discovery science. The proxy also describes a Lead Independent Director and fully independent key board committees, which partly offsets the combined Chair and CEO role.

Which KPIs should researchers monitor?

For BMS, the most useful KPIs are not store counts, traffic, or software retention. They are product revenue mix, exclusivity exposure, gross-to-net pressure, R&D productivity, cash conversion, and balance-sheet flexibility. A DCF model should separate products likely to decline from products that may compound, rather than applying one uniform revenue growth rate to the whole company.

Which valuation drivers matter most?

What risks could change Bristol Myers Squibb's outlook?

The risk profile is sector-specific. BMS faces patent cliffs, generic and biosimilar competition, regulatory approval uncertainty, pricing and reimbursement pressure, clinical trial failure, manufacturing complexity, product liability, litigation, and acquisition integration risk. The central risk is not that demand for medicines disappears; it is that cash flows tied to specific products can compress quickly when exclusivity, access, or clinical differentiation weakens.

What opportunities could offset the pressure?

The opportunity side is the mirror image of the risk profile. If BMS can keep the Growth Portfolio compounding, expand indications for oncology and hematology assets, scale Cobenfy in neuroscience, grow Camzyos in obstructive hypertrophic cardiomyopathy, and convert late-stage assets into approvals, the revenue base can become less dependent on older products. Management's 2026 guidance in the Q1 presentation reaffirmed total revenue of about $46.0B to $47.5B and non-GAAP diluted EPS of $6.05 to $6.35, while noting that revenue was tracking toward the upper end of the range. That is guidance, not a guarantee, but it defines what investors will test in subsequent quarters.

Why does Bristol Myers Squibb matter for valuation?

BMS is a useful DCF case because the visible accounting numbers and the economic story diverge in important ways. FY2025 revenue was roughly flat, but the mix changed materially: Growth Portfolio revenue rose 17% to $26.409B while Legacy Portfolio revenue fell 15% to $21.785B. A simple top-line extrapolation would miss the internal transition that determines terminal value.

How should a student model the business?

A more credible model separates at least four blocks: Eliquis, Opdivo and oncology combinations, other Growth Portfolio brands, and declining legacy products. It should then model gross-to-net pressure, R&D and acquired IPRD, amortization separately from cash economics, capex, working capital, debt service, and dividends. The key judgment is not whether BMS is a “good” or “bad” company; it is how long cash flows from mature products last and how much of the pipeline converts into durable, reimbursed, patent-protected revenue.

What is the key takeaway from Bristol Myers Squibb analysis?

Bristol Myers Squibb is not a clean growth company and not a simple value stock. It is a large innovative-medicine company in the middle of a portfolio handoff. The attractive part of the story is scale: $48.194B of FY2025 revenue, $14.156B of FY2025 operating cash flow, multiple multibillion-dollar products, a broad therapeutic footprint, and a deep pipeline. The difficult part is durability: Eliquis concentration, Revlimid decline, pricing pressure, R&D uncertainty, and $33.607B of net debt at March 31, 2026.

What should students and investors watch next?

• Whether Growth Portfolio revenue continues to grow faster than the Legacy Portfolio declines.
• Whether Eliquis demand, pricing, and exclusivity outcomes remain favorable enough to fund the transition.
• Whether Cobenfy, Camzyos, Reblozyl, Breyanzi, and Opdivo Qvantig scale into larger cash-flow contributors.
• Whether R&D readouts in 2026 and 2027 improve the perceived replacement value of the pipeline.
• Whether operating cash flow normalizes after Q1 2026 rebate and working-capital pressure.
• Whether management balances dividends, debt reduction, buybacks, and business development without weakening flexibility.